| 1. Hua X, Deuse T, Chen YJ, Wulff H, Stubbendorff M, Köhler R, Miura H, Länger F, Reichenspurner H, Robbins RC et al.. (2013) The potassium channel KCa3.1 as new therapeutic target for the prevention of obliterative airway disease.. Transplantation, 95 (2): (285-92). [PMID:23325003] |
| 2. Yu ZH, Xu JR, Wang YX, Xu GN, Xu ZP, Yang K, Wu DZ, Cui YY, Chen HZ. (2013) Targeted inhibition of KCa3.1 channel attenuates airway inflammation and remodeling in allergic asthma.. Am J Respir Cell Mol Biol, 48 (6): (685-93). [PMID:23492185] |
| 3. Koshy S, Wu D, Hu X, Tajhya RB, Huq R, Khan FS, Pennington MW, Wulff H, Yotnda P, Beeton C. (2013) Blocking KCa3.1 channels increases tumor cell killing by a subpopulation of human natural killer lymphocytes.. PLoS ONE, 8 (10): (e76740). [PMID:24146918] |
| 4. Chimote AA, Hajdu P, Kucher V, Boiko N, Kuras Z, Szilagyi O, Yun YH, Conforti L. (2013) Selective inhibition of KCa3.1 channels mediates adenosine regulation of the motility of human T cells.. J Immunol, 191 (12): (6273-80). [PMID:24227782] |
| 5. Chen YJ, Lam J, Gregory CR, Schrepfer S, Wulff H. (2013) The Ca²⁺-activated K⁺ channel KCa3.1 as a potential new target for the prevention of allograft vasculopathy.. PLoS ONE, 8 (11): (e81006). [PMID:24312257] |
| 6. Roach KM, Duffy SM, Coward W, Feghali-Bostwick C, Wulff H, Bradding P. (2013) The K+ channel KCa3.1 as a novel target for idiopathic pulmonary fibrosis.. PLoS ONE, 8 (12): (e85244). [PMID:24392001] |
| 7. Crottès D, Félix R, Meley D, Chadet S, Herr F, Audiger C, Soriani O, Vandier C, Roger S, Angoulvant D et al.. (2016) Immature human dendritic cells enhance their migration through KCa3.1 channel activation.. Cell Calcium, 59 (4): (198-207). [PMID:27020659] |
| 8. Glaser N, Little C, Lo W, Cohen M, Tancredi D, Wulff H, O'Donnell M. (2017) Treatment with the KCa3.1 inhibitor TRAM-34 during diabetic ketoacidosis reduces inflammatory changes in the brain.. Pediatr Diabetes, 18 (5): (356-366). [PMID:27174668] |
| 9. Ohya S, Fukuyo Y, Kito H, Shibaoka R, Matsui M, Niguma H, Maeda Y, Yamamura H, Fujii M, Kimura K et al.. (2014) Upregulation of KCa3.1 K(+) channel in mesenteric lymph node CD4(+) T lymphocytes from a mouse model of dextran sodium sulfate-induced inflammatory bowel disease.. Am J Physiol Gastrointest Liver Physiol, 306 (10): (G873-85). [PMID:24674776] |
| 10. Chen YJ, Nguyen HM, Maezawa I, Grössinger EM, Garing AL, Köhler R, Jin LW, Wulff H. (2016) The potassium channel KCa3.1 constitutes a pharmacological target for neuroinflammation associated with ischemia/reperfusion stroke.. J Cereb Blood Flow Metab, 36 (12): (2146-2161). [PMID:26661208] |
| 11. Zhang S, Wang X, Ju C, Zhu L, Du Y, Gao C. (2016) Blockage of K(Ca)3.1 and Kv1.3 channels of the B lymphocyte decreases the inflammatory monocyte chemotaxis.. Int Immunopharmacol, 31 (3): (266-71). [PMID:26795234] |
| 12. Lin H, Zheng C, Li J, Yang C, Hu L. (2014) Ca2+ -activated K+ channel-3.1 blocker TRAM-34 alleviates murine allergic rhinitis.. Int Immunopharmacol, 23 (2): (642-8). [PMID:25466273] |
| 13. Friebel K, Schönherr R, Kinne RW, Kunisch E. (2015) Functional role of the KCa3.1 potassium channel in synovial fibroblasts from rheumatoid arthritis patients.. J Cell Physiol, 230 (7): (1677-88). [PMID:25545021] |
| 14. Shao Z, Gaurav R, Agrawal DK. (2015) Intermediate-conductance calcium-activated potassium channel KCa3.1 and chloride channel modulate chemokine ligand (CCL19/CCL21)-induced migration of dendritic cells.. Transl Res, 166 (1): (89-102). [PMID:25583444] |
D1524067